The State of Ohio Board of Pharmacy (SOBP) requests comments on recently drafted rules to establish requirements of physician-established protocols and training requirements for pharmacists to administer dangerous drugs by injection. The rules are necessary because of passage of Senate Bill 332 of the 131st General Assembly.
- An opioid antagonist used for treatment of drug addiction and administered in a long-acting or extended-release form
- An opioid antagonist may also be administered for the treatment of alcohol dependence in accordance with approved labeling by the United States Food and Drug Administration
- An antipsychotic drug administered in a long-acting or extended-release form
- Hydroxyprogesterone caproate for pregnant women
- Medroxyprogesterone acetate for non-pregnant women
- Cobalamin.
- Successfully complete a course in the administration of drugs
- Receive and maintain certification to perform basic life-support procedures by successfully completing a basic life-support training course certified by the American Red Cross, the American Heart Association, or other training course approved by the board
- Practice in accordance with a physician protocol.
Each time a pharmacist administers a drug pursuant to this rule, the pharmacist must notify the physician who prescribed the drug within seven days that the drug has been administered to the individual.
View a copy of the business impact analysis and the rule.
Comments on the proposed rule will be accepted until close of business on Tuesday, May 2, via email to Cameron.mcnamee@pharmacy.ohio.gov and csipubliccomments@governor.ohio.gov.